A Clinical Trial Of Irrinotecan Plus Oxaliplatin Compared With Docetaxel Plus Oxaliplatin For Advanced Epithelial Ovarian Cancer

Objective: To compare irinotecan and oxaliplatin(CPT-P)with docetaxel plus oxaliplatin(TP)in patients with advanced epithelial ovarian cancer after initial surgery,this study evaluated the efficacy and toxicity of the two regiments.Methods: Total forty-three gynecological patients from the Fourth Hospital of Hebei Medical University were clinically and pathologically eligible for evaluation.Twenty-five patients were assigned to receive irinotecan 180mg/m2 plus oxaliplatin 130mg/m2 on day 1(CPT-P group)every three weeks for six cycles and eighteen patients were assigned to receive docetaxel 70mg/m2 plus oxaliplatin 130mg/m2 on day 1 every three weeks for six cycles(TP group).Results:1 Satisfactory decreasing of CA125 level was recorded in 34 of 43(79.1%)eligible patients.92.0%(23/25)of patients is in CPT-P group and 61.1%(11/18)of patients in TP group(P<0.05).2 Relapse frequency is 32.0% in CPT-P group and 50% in TP group(P>0.05).3 With a median follow-up of 25.9 months,2-year progression-free survival rates were 60.8% in CPT-P group and 48.6% in TP group(P<0.05).4 Two year overall survival rates were 82.1% with CPT-P and 87.7%with TP(P<0.05).5 Grade 3/4 diarrhea occurred more frequently with CPT-P,whereas grade 3/4 neutropenia,hypoesthesia and alopecia occurred more frequently with TP.No treatment-related deaths occurred.Conclusions:1 CPT-P and TP had equal efficacy.2 The decreasing of CA125 level in CPT-P was more satisfied.3 Both regiments were well tolerated,but the toxicity differed.4 Further study is needed in terms of recurrence,PFS and OS.